Search 

Top MNC

Private investment firm

Heathcare PE fund

Photon Fund is a venture capital institution concentrating on technology and innovation. Strategically located in Shenzhen, with office in Beijing and Silicon Valley, which are the most creative cities, Photon Fund invests in global scale.

Located in Jinan, Qilu Pharmaceutical is one of the leading pharmaceutical companies in China. It focuses on developing, manufacturing and marketing of generic drugs and active pharmaceutical ingredients in the therapeutic areas of Oncology, Cerebrovascular & Cardiovascular, Infections, Psychological&Neurological System, Respiratory System, Ophthalmological Diseases, etc. Qilu has more than 8000 employees, 70% of which have the college degree or above.

Qilu pharmaceutical has always been sticking to the innovative development strategy. Guided by the market demand and the product innovation, Qilu has established extensive cooperation with domestic and foreign partners on a series of R&D projects. Qilu pays high attention to the introduction and cultivation of talents and has built a highly qualified R&D team with professional and efficient R&D capabilities, More than 100 national new drugs have been successfully developed, which constitutes the reasonable production line for the future development of Qilu. A number of technological achievements have obtained the national and provincial scientific & technological progress awards and created good social benefit.

Qilu Pharmaceutical has eight manufacturing sites covering an area of more than 2800,000 ㎡for finished dosage forms, chemical synthesis, genetic-engineering, fermentation, etc. The modern workshops are located in the manufacturing sites where the automatic production lines, key equipments and analytical instruments are imported from the leading suppliers all over the world. Now Qilu Pharmaceutical has been one of the leading global suppliers of Antibiotic APIs and Oncology APIs with huge capacity and good quality.

Qilu pharmaceutical has always been committing itself to providing the high-quality products to the patients and the society. Thanks to the integrated and stringent system of quality control and quality assurance, the company has been the leader of cGMP implementation in China. Its non-sterile APIs (fermentation and chemical synthesis), sterile APIs and comprehensive finished dosages have been respectively approved by USFDA, European Directorate for the Quality of Medicines (EDQM), Therapeutic Goods Administration (TGA) of Australia, Medicines and Healthcare products Regulatory Agency (MHRA) of UK, Medicines Control Council (MCC) of South Africa, and some other national competent authorities.

Qilu Pharmaceutical has an integrated product structure and value chain with over 160 launched products. The company has established a comprehensive domestic and overseas sales network. The global presence has covered North America, Europe, CIS countries, South America, Asia, South Africa and Middle East. The valuable brand of the company has been well built with the quality products and good services.

About Rius Medical: Rius Medical is designing and developing a new generation of Commercial cell therapies positioned at the crossroads of two high-potential programs: (1.) genetically engineering red blood cells for an entirely new class of cellular medicines and (2.) potent NK-cell therapy products. Due to their mechanism of action, engineered red blood cells demonstrated treatments for wide range of patients from starving cancer cells to targeting autoimmune diseases. Building on exceptional progress in cell therapies, Rius Medical is in a unique position to offer Third-Generation red blood cells for drug delivery that addresses Rare Diseases, Oncology and Autoimmune Diseases like type 1 diabetes! Furthermore, harnessing the unique power of natural killer (NK) cells enables the treatment of cancer and infectious diseases such as Influenza virus or SARS-Coronavirus (i.e. COVID-19 pandemic). That’s right, NK-cells as vaccine delivery NOT for antibodies but for “memory T cells” activation!

Pharma and diagnostics

RNA(R&D)

simcere pharmaceutical group

The Sino-American Pharmaceutical Professionals Association (SAPA) was established in 1993 and is headquartered in the center of the pharmaceutical corridor in New Jersey, USA.  Since its inception, SAPA rapidly became one of the most active Chinese professional associations in the US with eight chapters and more than 6,000 members.

SAPA’s members are primarily from large and mid-sized pharmaceutical and biotech companies in the US, with areas of expertise covering almost every aspect of pharmaceutical research and development as well as production.

The organization’s large membership base and their superb scientific and technical abilities has allowed SAPA to be a key source for knowledge exchange on the latest developments in the pharmaceutical, biotechnology, and generic drug industries.